Tat-NR2B9c

Research use only, not for human use.

Tat-NR2B9c (NA-1) is a neuroprotective agent; exhibits high-affinity binding to the second PDZ domain of PSD-95.

Tat-NR2B9c (NA-1) is a neuroprotective agent; exhibits high-affinity binding to the second PDZ domain of PSD-95; inhibits NR2A-NR2C/PSD-95 interactions (IC50=1-10 uM) and nNOS/PSD-95 interaction (IC50=200 nM).Stroke Phase 3 Clinical.

Tat-NR2B9c is a PSD-95 inhibitor, with an EC50 of 6.7 nM for PSD-95d2, representing a >100-fold higher affinity for this domain than for PSD-95d1 (EC50, 0.67 μM). Tat-NR2B9c inhibits NMDAR2A, NMDAR2B, and NMDAR2C binding to PSD-95, with IC50s of 0.5 μM, ～8 μM, and 0.75 μM, respectively.Tat-NR2B9c also blocks the interaction between PSD-95 and nNOS with an IC50 of ～0.2 μM. Tat-NR2B9c reduces association of PSD-95 with GluN2B by ～50% in the YAC128 striatum, decreases NMDA-induced p38 activation in YAC128 striatal tissue, but shows no effect on the NMDA-induced JNK activation.

Tat-NR2B9c (10?nmol/g, i.v.) reduces infarction volume of male C57BL/6 mice, but has no effect at 3?nM/g.

NA-1

Others

Other Targets

Other Targets

Neurological Disease

Stroke

500992-11-0

2518.88

C105H188N42O30

>98% (HPLC)

H2O

CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(CC(=O)O)C(=O)NC(C(C)C)C(=O)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CCCCN)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCC(=O)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)C(CCCNC(=N)N)NC(=O)CNC(=O)C(CC1=CC=C(C=C1)O)N

L-Valine, L-tyrosylglycyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L-arginyl-L-arginyl-L-arginyl-L-lysyl-L-leucyl-L-seryl-L-seryl-L-isoleucyl-L-α-glutamyl-L-seryl-L-α-aspartyl-

(-20℃)

With Ice Pack

≥ 2 years